NICE Endorses Linzagolix for NHS Endometriosis Care

The National Institute for Health and Care Excellence (NICE) has approved linzagolix combined with hormonal add-back therapy for endometriosis treatment within the NHS, expanding therapeutic options for an estimated 1.5 million women in the UK affected by this chronic condition. Clinical trials have substantiated that linzagolix effectively reduces both dysmenorrhea and non-menstrual pelvic pain in … Read more

CAT-os Tool Addresses Global Orthopedic Surgery Gap

A validated capacity assessment tool designed to strengthen orthopedic surgery capabilities in low- and middle-income countries (LMICs) has demonstrated excellent reliability and practical utility in pilot testing, addressing a critical healthcare disparity that affects millions globally. The Capacity Assessment Tool for Orthopedic Surgery (CAT-os) provides systematic evaluation frameworks for surgical outreach programs targeting regions where … Read more

Medicare Expands Signatera Genome MRD Assay Coverage

Medicare has approved coverage for Natera’s genome-based Signatera molecular residual disease (MRD) assay under LCD L38779, extending access to beneficiaries across six cancer indications. The coverage applies to colorectal, breast, bladder, ovarian, and lung cancers, as well as pan-cancer immunotherapy monitoring, aligning with the scope of Natera’s original Signatera test. This regulatory milestone positions the … Read more

CND’s Syn-One Test Shows 75% Detection in Sleep Disorder

CND Life Sciences reported baseline results from its NIH-sponsored Syn-Sleep Study, demonstrating the Syn-One Test’s ability to detect phosphorylated alpha-synuclein (P-SYN) in 75% of patients with idiopathic REM sleep behavior disorder (iRBD). The 24-month longitudinal study enrolled 80 participants across 11 US sites, representing a critical validation step for cutaneous biomarker detection in prodromal neurodegenerative … Read more

Stryker Acquires Inari Medical: Strategic Expansion into Peripheral Vascular Treatment Market

Stryker Completes $3.1 Billion Acquisition of Inari Medical, Entering High-Growth Venous Thrombectomy Market Stryker Corporation (NYSE: SYK), a global leader in medical technology, has completed its acquisition of Inari Medical, Inc. (NASDAQ: NARI), a pioneering developer of devices for venous thromboembolism (VTE) treatment. This strategic $3.1 billion acquisition marks Stryker’s entry into the rapidly growing … Read more

Bain Capital Acquires Mitsubishi Tanabe Pharma

Bain Capital, a leading global private investment firm with approximately $160 billion in assets under management, has announced its agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC), a renowned Japanese pharmaceutical company with over 300 years of heritage. This transaction represents one of Bain Capital’s largest investments in the pharmaceutical sector and demonstrates its continued … Read more

Pure Health Acquires 60% Stake in Hellenic Health Care Group in $2.3 Billion Deal, Expanding Global Healthcare Reach

On Jan. 27, 2025, Pure Health has agreed to acquire a 60% stake in Hellenic Health Care Group (HHG). The transaction values. 2.3 billion at USD. Pure Health is the largest healthcare group in the Middle East. Hellenic Health Care Group is the largest private healthcare provider in Greece and Cyprus. Pure Health Partnering with … Read more

Eli Lilly Shakes Up JPM25 with $2.5B Scorpion Buyout in Breast Cancer Battle

Eli Lilly kicked off the 2025 J.P. Morgan Healthcare Conference with a strategic acquisition of Scorpion Therapeutics, securing its PI3Kα pipeline for up to $2.5 billion in upfront payments and milestones. The deal marks a bold move in Lilly’s quest to compete with Novartis and Roche in the lucrative breast cancer market. A Renewed Push … Read more

Johnson & Johnson Steals the Spotlight at JPM Conference with $14.6B Intra-Cellular Therapies Acquisition

On Monday, Johnson & Johnson (J&J) made headlines at the J.P. Morgan Healthcare Conference by announcing its agreement to acquire Intra-Cellular Therapies, a pioneering biotech company specializing in treatments for brain diseases. The deal, valued at $132 per share or approximately $14.6 billion, marks the largest biotechnology acquisition since early 2023. A Strategic Play in … Read more

GSK snaps up IDRx for up to $1.15B

Britan-based pharmaceutical giant GSK has agreed to acquire 100% of the outstanding equity interests (including all options and other incentive equity) in IDRx, a US-based, clinical-stage biopharmaceutical company focused on developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST). The acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) being developed … Read more